| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $0 | 0 | – |
Sells | $0 | 0 | – |
Novavax, Inc. is a biotechnology firm dedicated to discovering, developing, and commercializing vaccines aimed at preventing serious infectious diseases and addressing critical health needs. The company's diverse pipeline includes NVX-CoV2373, a coronavirus vaccine candidate currently undergoing two Phase III trials, one Phase IIb, and one Phase I/II trial. Also featured is NanoFlu, a nanoparticle-based seasonal quadrivalent influenza vaccine in Phase 3 clinical trials. Furthermore, Novavax is advancing ResVax, a respiratory syncytial virus …
Over the last 12 months, insiders at Novavax, Inc. have bought $0 and sold $0 worth of Novavax, Inc. stock.
On average, over the past 5 years, insiders at Novavax, Inc. have bought $43,042 and sold $4.78M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 1,000 shares for transaction amount of $6,500 was made by Glenn Gregory M (President, R&D) on 2023‑03‑10.
| 2024-12-31 | Sale | YOUNG JAMES F | director | 5,400 0.0033% | $8.00 | $43,200 | -7.46% | |
| 2024-12-24 | Sale | YOUNG JAMES F | director | 4,600 0.0029% | $8.48 | $39,008 | -12.22% | |
| 2024-12-13 | Sale | King Rachel K. | director | 4,150 0.0026% | $9.02 | $37,435 | -16.79% | |
| 2024-06-21 | Sale | YOUNG JAMES F | director | 7,500 0.0045% | $14.09 | $105,675 | -37.86% | |
| 2024-06-18 | Sale | YOUNG JAMES F | director | 7,500 0.0044% | $13.72 | $102,881 | -36.66% | |
| 2024-06-17 | Sale | Dubovsky Filip | President, R&D | 13,904 0.0086% | $14.47 | $201,164 | -37.65% | |
| 2024-05-14 | Sale | Dubovsky Filip | President, R&D | 47,312 0.0347% | $13.90 | $657,637 | -30.75% | |
| 2023-03-10 | Glenn Gregory M | President, R&D | 1,000 0.0012% | $6.50 | $6,500 | +9.13% | ||
| 2023-03-07 | Glenn Gregory M | President, R&D | 2,000 0.0023% | $7.04 | $14,088 | +1.87% | ||
| 2023-03-06 | Glenn Gregory M | President, R&D | 3,000 0.0036% | $7.48 | $22,454 | -2.61% | ||
| 2022-03-31 | Sale | YOUNG JAMES F | 300 0.0004% | $75.10 | $22,531 | -69.53% | ||
| 2022-01-03 | Sale | Herrmann John A III | EVP, Chief Legal Officer | 5,000 0.0064% | $140.91 | $704,534 | -65.85% | |
| 2021-12-31 | Sale | YOUNG JAMES F | director | 3,750 0.0049% | $144.16 | $540,601 | -64.98% | |
| 2021-12-20 | Sale | Herrmann John A III | EVP, Chief Legal Officer | 5,000 0.0075% | $230.00 | $1.15M | -74.34% | |
| 2021-12-15 | Sale | Glenn Gregory M | President, R&D | 1,686 0.0022% | $174.13 | $293,584 | -71.05% | |
| 2021-12-07 | Sale | Glenn Gregory M | President, R&D | 8,250 0.0101% | $170.14 | $1.4M | -70.62% | |
| 2021-12-01 | Sale | Herrmann John A III | EVP, Chief Legal Officer | 5,000 0.0067% | $196.19 | $980,944 | -71.88% | |
| 2021-11-30 | Sale | Glenn Gregory M | President, R&D | 8,942 0.0115% | $203.20 | $1.82M | -73.89% | |
| 2021-11-29 | Sale | Herrmann John A III | EVP, Chief Legal Officer | 5,000 0.0078% | $228.72 | $1.14M | -71.88% | |
| 2021-11-26 | Sale | Glenn Gregory M | President, R&D | 2,083 0.0028% | $218.07 | $454,247 | -74.84% |
| Monath Thomas P | director | 3225366 1.9554% | $31.22M | 1 | 0 | |
| TANANBAUM JAMES B | director | 3151818 1.9108% | $30.51M | 1 | 0 | |
| DOUGLAS RICHARD | director | 550000 0.3334% | $5.32M | 7 | 0 | +19.72% |
| BOUDREAUX GAIL | director | 200000 0.1213% | $1.94M | 1 | 0 | <0.0001% |
| Singhvi Rahul | President, CEO | 113104 0.0686% | $1.09M | 2 | 2 | <0.0001% |
| Hahn Timothy Jon | SVP, Manufacturing | 110485 0.067% | $1.07M | 7 | 0 | +63.56% |
| LAMBERT JOHN A | director | 80000 0.0485% | $774,400.00 | 1 | 1 | |
| Robinson Jim | VP, Tech. & Quality Operations | 77590 0.047% | $751,071.20 | 3 | 0 | <0.0001% |
| Wilson Russell P | SVP, Business Development | 64939 0.0394% | $628,609.52 | 3 | 0 | +25.49% |
| YOUNG JAMES F | director | 51760 0.0314% | $501,036.80 | 5 | 11 | +66.45% |
| PHILLIPS BARCLAY A | SVP, Chief Financial Officer | 38669 0.0234% | $374,315.92 | 12 | 2 | +22.22% |
| MARSH JOHN O JR | director | 36000 0.0218% | $348,480.00 | 2 | 0 | +156.16% |
| SIMS NELSON M | Former President & CEO | 25000 0.0152% | $242,000.00 | 2 | 0 | <0.0001% |
| Erck Stanley C | President and CEO | 23879 0.0145% | $231,148.72 | 12 | 11 | +13.31% |
| Stigliano Len F | VP, CFO, Treasurer | 20554 0.0125% | $198,962.72 | 2 | 0 | <0.0001% |
| DRISCOLL FREDERICK W | VP, CFO & Treasurer | 20000 0.0121% | $193,600.00 | 1 | 0 | +0.73% |
| Heaton Penny | VP & Chief Medical Officer | 18667 0.0113% | $180,696.56 | 2 | 1 | <0.0001% |
| King Rachel K. | director | 14770 0.009% | $142,973.60 | 2 | 1 | <0.0001% |
| Glenn Gregory M | President, R&D | 14473 0.0088% | $140,098.64 | 23 | 43 | +73.14% |
| LAZARUS J MICHAEL MD | director | 11927 0.0072% | $115,453.36 | 2 | 1 | +29.29% |
| Johnston Thomas Scott | Vice President, Strategy | 11000 0.0067% | $106,480.00 | 1 | 1 | |
| MCMANUS MICHAEL A JR | director | 5951 0.0036% | $57,605.68 | 6 | 3 | +34.83% |
| LYNCH FORD R | Sr. VP Marketing and Sales | 4300 0.0026% | $41,624.00 | 1 | 0 | <0.0001% |
| Herrmann John A III | EVP, Chief Legal Officer | 3845 0.0023% | $37,219.60 | 5 | 22 | +8.64% |
| Trizzino John | EVP, CCO and CBO | 2546 0.0015% | $24,645.28 | 10 | 22 | <0.0001% |
| EVANS GARY C | director | 0 0% | $0 | 20 | 15 | +112.18% |
Novavax, Inc. (NVAX) | $8,217,280 | 112 | 46.33% | $1.6B |
$54,660,406 | 66 | 22.24% | $1.5B | |
$530,111,731 | 35 | 8.69% | $1.51B | |
$27,136,525 | 32 | 36.73% | $1.64B | |
$4,431,947 | 22 | 36.10% | $1.46B |
| Increased Positions | 110 | +36.67% | 26M | +24.82% |
| Decreased Positions | 123 | -41% | 11M | -10.88% |
| New Positions | 39 | New | 1M | New |
| Sold Out Positions | 43 | Sold Out | 7M | Sold Out |
| Total Postitions | 287 | -4.33% | 118M | +13.94% |
| Vanguard Group Inc | $108,337.00 | 9.38% | 15.19M | -238,649 | -1.55% | 2025-09-30 |
| Blackrock, Inc. | $91,072.00 | 7.89% | 12.77M | +29,898 | +0.23% | 2025-09-30 |
| Shah Capital Management | $84,218.00 | 7.29% | 11.81M | +300,000 | +2.61% | 2025-09-30 |
| State Street Corp | $51,313.00 | 4.44% | 7.2M | +372,468 | +5.46% | 2025-09-30 |
| Sanofi | $49,058.00 | 4.25% | 6.88M | 0 | 0% | 2025-09-30 |
| D. E. Shaw & Co., Inc. | $30,474.00 | 2.64% | 4.27M | +333,119 | +8.45% | 2025-09-30 |
| Coatue Management Llc | $27,358.00 | 2.37% | 3.84M | 0 | 0% | 2025-09-30 |
| Geode Capital Management, Llc | $27,037.00 | 2.34% | 3.79M | +23,711 | +0.63% | 2025-09-30 |
| Ubs Group Ag | $25,071.00 | 2.17% | 3.52M | +1M | +55.85% | 2025-09-30 |
| Bank Of America Corp /De/ | $22,111.00 | 1.91% | 3.1M | -34,315 | -1.09% | 2025-09-30 |